No Evidence for Clade I Monkeypox Virus Circulation, Belgium
Emerg Infect Dis. 2024 Feb;30(2):402. doi: 10.3201/eid3002.231746. Epub 2024 Jan 8.NO ABSTRACTPMID:38190761 | PMC:PMC10826767 | DOI:10.3201/eid3002.231746 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 8, 2024 Category: Infectious Diseases Authors: Laurens Liesenborghs Jasmine Coppens Christophe Van Dijck Isabel Brosius Irith De Baetselier Koen Vercauteren Marjan Van Esbroeck Source Type: research

Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic
In this report, we highlight key challenges for the development of integrated models of surveillance. We discuss the relative strengths and limitations of different surveillance practices and studies as well as their contribution to epidemiologic assessment, forecasting, and public health decision-making.PMID:38190760 | DOI:10.3201/eid3002.230768 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 8, 2024 Category: Infectious Diseases Authors: Oliver Eales Michael J Plank Benjamin J Cowling Benjamin P Howden Adam J Kucharski Sheena G Sullivan Katelijn Vandemaele Cecile Viboud Steven Riley James M McCaw Freya M Shearer Source Type: research

No Evidence for Clade I Monkeypox Virus Circulation, Belgium
Emerg Infect Dis. 2024 Jan 8;30(2). doi: 10.3201/eid3002.231746. Online ahead of print.NO ABSTRACTPMID:38190761 | DOI:10.3201/eid3002.231746 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 8, 2024 Category: Infectious Diseases Authors: Laurens Liesenborghs Jasmine Coppens Christophe Van Dijck Isabel Brosius Irith De Baetselier Koen Vercauteren Marjan Van Esbroeck Source Type: research

Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230835. Online ahead of print.ABSTRACTWe evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizatio...
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Yuan Bai Zhanwei Du Lin Wang Eric H Y Lau Isaac Chun-Hai Fung Petter Holme Benjamin J Cowling Alison P Galvani Robert M Krug Lauren Ancel Meyers Source Type: research

Adapting COVID-19 Contact Tracing Protocols to Accommodate Resource Constraints, Philadelphia, Pennsylvania, USA, 2021
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230988. Online ahead of print.ABSTRACTBecause of constrained personnel time, the Philadelphia Department of Public Health (Philadelphia, PA, USA) adjusted its COVID-19 contact tracing protocol in summer 2021 by prioritizing recent cases and limiting staff time per case. This action reduced required staff hours to prevent each case from 21-30 to 8-11 hours, while maintaining program effectiveness.PMID:38181801 | DOI:10.3201/eid3002.230988 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Seonghye Jeon Lydia Watson-Lewis Gabriel Rainisch Chu-Chuan Chiu Fran çois M Castonguay Leah S Fischer Patrick K Moonan John E Oeltmann Bishwa B Adhikari Hannah Lawman Martin I Meltzer Source Type: research

Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230835. Online ahead of print.ABSTRACTWe evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizatio...
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Yuan Bai Zhanwei Du Lin Wang Eric H Y Lau Isaac Chun-Hai Fung Petter Holme Benjamin J Cowling Alison P Galvani Robert M Krug Lauren Ancel Meyers Source Type: research

Adapting COVID-19 Contact Tracing Protocols to Accommodate Resource Constraints, Philadelphia, Pennsylvania, USA, 2021
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230988. Online ahead of print.ABSTRACTBecause of constrained personnel time, the Philadelphia Department of Public Health (Philadelphia, PA, USA) adjusted its COVID-19 contact tracing protocol in summer 2021 by prioritizing recent cases and limiting staff time per case. This action reduced required staff hours to prevent each case from 21-30 to 8-11 hours, while maintaining program effectiveness.PMID:38181801 | DOI:10.3201/eid3002.230988 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Seonghye Jeon Lydia Watson-Lewis Gabriel Rainisch Chu-Chuan Chiu Fran çois M Castonguay Leah S Fischer Patrick K Moonan John E Oeltmann Bishwa B Adhikari Hannah Lawman Martin I Meltzer Source Type: research

Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230835. Online ahead of print.ABSTRACTWe evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizatio...
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Yuan Bai Zhanwei Du Lin Wang Eric H Y Lau Isaac Chun-Hai Fung Petter Holme Benjamin J Cowling Alison P Galvani Robert M Krug Lauren Ancel Meyers Source Type: research

Adapting COVID-19 Contact Tracing Protocols to Accommodate Resource Constraints, Philadelphia, Pennsylvania, USA, 2021
Emerg Infect Dis. 2024 Jan 5;30(2). doi: 10.3201/eid3002.230988. Online ahead of print.ABSTRACTBecause of constrained personnel time, the Philadelphia Department of Public Health (Philadelphia, PA, USA) adjusted its COVID-19 contact tracing protocol in summer 2021 by prioritizing recent cases and limiting staff time per case. This action reduced required staff hours to prevent each case from 21-30 to 8-11 hours, while maintaining program effectiveness.PMID:38181801 | DOI:10.3201/eid3002.230988 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 5, 2024 Category: Infectious Diseases Authors: Seonghye Jeon Lydia Watson-Lewis Gabriel Rainisch Chu-Chuan Chiu Fran çois M Castonguay Leah S Fischer Patrick K Moonan John E Oeltmann Bishwa B Adhikari Hannah Lawman Martin I Meltzer Source Type: research

Inferring Incidence of Unreported SARS-CoV-2 Infections Using Seroprevalence of Open Reading Frame 8 Antigen, Hong Kong
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231332. Online ahead of print.ABSTRACTWe tested seroprevalence of open reading frame 8 antigens to infer the number of unrecognized SARS-CoV-2 Omicron infections in Hong Kong during 2022. We estimate 33.6% of the population was infected, 72.1% asymptomatically. Surveillance and control activities during large-scale outbreaks should account for potentially substantial undercounts.PMID:38167176 | DOI:10.3201/eid3002.231332 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Shi Zhao Chris Ka Pun Mok Yun Sang Tang Chunke Chen Yuanxin Sun Ka Chun Chong David S C Hui Source Type: research

Phylogenomics of Dengue Virus Isolates Causing Dengue Outbreak, S ão Tomé and Príncipe, 2022
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231316. Online ahead of print.ABSTRACTWe determined that the dengue outbreak in São Tomé and Príncipe during 2022 was caused by dengue virus serotype 3 genotype III. Phylogenomic analyses showed that the outbreak strain was closely related to the newly identified GIII-American-II lineage and that the virus probably was introduced from the Americas.PMID:38167202 | DOI:10.3201/eid3002.231316 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Lazismino L ázaro Doris Winter Katia Toancha Adjaia Borges Anabela Gon çalves Asmiralda Santos Marcos do Nascimento Nilton Teixeira Yardlene Sacramento Sequeira Anery Katia Lima Bakissy da Costa Pina Andreza Batista de Sousa J ürgen May Rosa Maria Afon Source Type: research

Rebound of Gonorrhea after Lifting of COVID-19 Preventive Measures, England
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231148. Online ahead of print.ABSTRACTAfter lifting of all COVID-19 preventive measures in England in July 2021, marked, widespread increases in gonorrhea diagnoses, but not testing numbers, were observed, particularly in persons 15-24 years of age. Continued close surveillance and public health messaging to young persons are needed to control and prevent gonorrhea transmission.PMID:38167386 | DOI:10.3201/eid3002.231148 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Holly Fountain Stephanie J Migchelsen Hannah Charles Tika Ram Helen Fifer Hamish Mohammed Katy Sinka Source Type: research

Inferring Incidence of Unreported SARS-CoV-2 Infections Using Seroprevalence of Open Reading Frame 8 Antigen, Hong Kong
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231332. Online ahead of print.ABSTRACTWe tested seroprevalence of open reading frame 8 antigens to infer the number of unrecognized SARS-CoV-2 Omicron infections in Hong Kong during 2022. We estimate 33.6% of the population was infected, 72.1% asymptomatically. Surveillance and control activities during large-scale outbreaks should account for potentially substantial undercounts.PMID:38167176 | DOI:10.3201/eid3002.231332 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Shi Zhao Chris Ka Pun Mok Yun Sang Tang Chunke Chen Yuanxin Sun Ka Chun Chong David S C Hui Source Type: research

Phylogenomics of Dengue Virus Isolates Causing Dengue Outbreak, S ão Tomé and Príncipe, 2022
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231316. Online ahead of print.ABSTRACTWe determined that the dengue outbreak in São Tomé and Príncipe during 2022 was caused by dengue virus serotype 3 genotype III. Phylogenomic analyses showed that the outbreak strain was closely related to the newly identified GIII-American-II lineage and that the virus probably was introduced from the Americas.PMID:38167202 | DOI:10.3201/eid3002.231316 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Lazismino L ázaro Doris Winter Katia Toancha Adjaia Borges Anabela Gon çalves Asmiralda Santos Marcos do Nascimento Nilton Teixeira Yardlene Sacramento Sequeira Anery Katia Lima Bakissy da Costa Pina Andreza Batista de Sousa J ürgen May Rosa Maria Afon Source Type: research

Rebound of Gonorrhea after Lifting of COVID-19 Preventive Measures, England
Emerg Infect Dis. 2024 Jan 2;30(2). doi: 10.3201/eid3002.231148. Online ahead of print.ABSTRACTAfter lifting of all COVID-19 preventive measures in England in July 2021, marked, widespread increases in gonorrhea diagnoses, but not testing numbers, were observed, particularly in persons 15-24 years of age. Continued close surveillance and public health messaging to young persons are needed to control and prevent gonorrhea transmission.PMID:38167386 | DOI:10.3201/eid3002.231148 (Source: Emerging Infectious Diseases)
Source: Emerging Infectious Diseases - January 3, 2024 Category: Infectious Diseases Authors: Holly Fountain Stephanie J Migchelsen Hannah Charles Tika Ram Helen Fifer Hamish Mohammed Katy Sinka Source Type: research